DOCSLIB.ORG

Prospec Product Catalog 2021 Prospec의 기술, 제품, 서비스를 선택하는데는 이유가 있습니다

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

ProSpec Product Catalog 2021 ProSpec의 기술, 제품, 서비스를 선택하는데는 이유가 있습니다. QUALITY PROTEINS for scientific discoveries WE'VE GOT CHEMISTRY part for life sciences BRIGHTEN YOUR RESEARCH 6,000 proteins at your fingertips List by Molecule Name .KUVD[/QNGEWNG0COG �칊�튾튪찋잖쐚찯짣흖흌쐚��XXXQSPTQFDCJPDPN흖튢�튾� ѣشۼࡒْɹ ࢒ɹٵܒ QNGEWNCT ࡅԘ/ ࢼૺ؞ୋ ࢼૺֵ 0COG #$% # $ % 1F8 Chagas CCH-002 Recombinant 1F8 Chagas 5μg 20μg 1mg 90,500 199,000 4,680,300 4-1BBL CYT-149 Recombinant Human 4-1BB Ligand 5μg 20μg 1mg 90,500 199,000 3,501,000 4-1BBL, His CYT-649 Recombinant Human 4-1BB Ligand, His Tag 5μg 20μg 1mg 112,200 220,800 3,600,400 4-1BBR CYT-463 Recombinant Human 4-1BB Receptor 5μg 20μg 1mg 90,500 199,000 3,501,000 4-1BBR, His CYT-137 Recombinant Human 4-1BB Receptor His Tag 5μg 20μg 1mg 112,200 220,800 4,879,000 4-1BBR, Sf9 CYT-931 Recombinant Human 4-1BB Receptor sf9 2μg 10μg 1mg 112,200 220,800 6,903,200 A2LD1 PRO-172 Recombinant Human AIG2-Like Domain 1 2μg 10μg 1mg 112,200 220,800 6,903,200 A2M PRO-551 Human Alpha-2 Macroglobulin Protein 200μg 1mg 10mg 90,500 317,500 2,307,700 AAGAB PRO-1479 Recombinant Human Alpha & Gamma-Adaptin Binding Protein 5μg 20μg 1mg 112,200 220,800 3,600,400 AAMDC PRO-2116 Recombinant Human Adipogenesis Associated, Mth938 Domain 5μg 20μg 1mg 112,200 220,800 3,600,400 Containing AARS ENZ-305 Recombinant Human Alanyl t-RNA Synthetase 5μg 20μg 1mg 112,200 220,800 5,204,400 AASDHPPT ENZ-008 Recombinant Human Aminoadipate-Semialdehyde 5μg 20μg 1mg 112,200 220,800 3,600,400 Dehydrogenase-Phosphopantetheinyl Transferase ABHD10 ENZ-612 Recombinant Human Abhydrolase Domain Containing 10 2μg 10μg 100μg 112,200 220,800 1,645,000 ABHD12B PRO-1998 Recombinant Human Abhydrolase Domain Containing 12B 5μg 20μg 1mg 112,200 220,800 3,600,400 ABHD14B ENZ-240 Recombinant Human Abhydrolase Domain Containing 14B 1μg 5μg 50μg 112,200 220,800 1,645,000 ABI3 PRO-1227 Recombinant Human ABI Family, Member 3 2μg 10μg 100μg 112,200 220,800 1,645,000 ABO ENZ-167 Recombinant Human ABO Blood Group 2μg 10μg 1mg 112,200 220,800 6,903,200 ABRACL PRO-1466 Recombinant Human ABRA C-Terminal Like 5μg 20μg 1mg 112,200 220,800 3,600,400 ACAA1 ENZ-251 Recombinant Human Acetyl-COA Acyltransferase 5μg 20μg 1mg 112,200 220,800 3,600,400 ACAA1 ANT-654 Mouse Anti Human Acetyl-COA Acyltransferase 5μg 20μg 100μg 112,200 220,800 664,800 ACAA2 ENZ-697 Recombinant Human Acetyl-COA Acyltransferase 2 2μg 10μg 1mg 112,200 220,800 6,903,200 ACAD8 ENZ-294 Recombinant Human Acyl-Coenzyme A Dehydrogenase 8 5μg 20μg 1mg 112,200 220,800 3,600,400 ACADL ENZ-190 Recombinant Human Acyl-CoA Dehydrogenase, Long Chain 2μg 10μg 1mg 112,200 220,800 6,903,200 ACADM ENZ-529 Recombinant Human Acyl-Coenzyme A Dehydrogenase, C-4 to 2μg 10μg 1mg 112,200 220,800 6,903,200 C-12 ACADS ENZ-467 Recombinant Human Acyl-Coenzyme A Dehydrogenase, C-2 to 2μg 10μg 1mg 112,200 220,800 6,903,200 C-3 ACADS ANT-689 Mouse Anti Human Acyl-Coenzyme A Dehydrogenase, C-2 to C- 5μg 20μg 100μg 112,200 220,800 664,800 3 ACADSB ENZ-643 Recombinant Human Acyl-CoA Dehydrogenase, Short Chain 2μg 10μg 1mg 112,200 220,800 6,903,200 ACADVL ENZ-250 Recombinant Human Acyl-CoA Dehydrogenase, Very Long 2μg 10μg 1mg 112,200 220,800 6,903,200 ACAT1 ENZ-665 Recombinant Human Acetyl-Coenzyme A acetyltransferase 1 5μg 20μg 1mg 112,200 220,800 3,600,400 ACAT1 ANT-101 Mouse Anti Human Acetyl-Coenzyme A acetyltransferase 1 5μg 20μg 100μg 90,500 199,000 643,200 ACAT2 ENZ-295 Recombinant Human Acetyl-Coenzyme A acetyltransferase 2 5μg 20μg 1mg 112,200 220,800 3,600,400 ACAT2 ANT-561 Mouse Anti Human Acetyl-Coenzyme A acetyltransferase 2 5μg 20μg 100μg 112,200 220,800 664,800 ACBD6 PRO-1734 Recombinant Human Acyl-CoA Binding Domain Containing 6 5μg 20μg 1mg 112,200 220,800 3,600,400 ࢂח Ѧط ࢂח Ѧط ࢂח Ѧط ACE ENZ-1156 Recombinant Human Angiotensin Converting Enzyme 2μg 10μg 1mg ࢂח Ѧط ࢂח Ѧط ࢂח Ѧط ACE2 (18-615) ENZ-1121 Recombinant Human Angiotensin Converting Enzyme 2 (18-615 1μg 5μg 10μg a.a.) ࢂח Ѧط ࢂח Ѧط ࢂח Ѧط ACE2 (18-740) ENZ-1125 Recombinant Human Angiotensin Converting Enzyme 2 (18-740 50μg 150μg 250μg a.a.) ࢂח Ѧط ࢂח Ѧط ࢂח Ѧط ACE2 (18-740), ENZ-1127 Recombinant Human Angiotensin Converting Enzyme 2 (18-740 1μg 5μg 50μg Biotin a.a.), Biotinylated ࢂח Ѧط ࢂח Ѧط ࢂח Ѧط ACE2 (18-740), ENZ-1126 Recombinant Human Angiotensin Converting Enzyme 2 (18-740 50μg 150μg 250μg Fc a.a.), Fc Tag ࢂח Ѧط ࢂח Ѧط ࢂח Ѧط ACE2 (19-740) ENZ-1122 Recombinant Human Angiotensin Converting Enzyme 2 (19-740 1μg 5μg 10μg a.a.) ACKA PKA-063 Recombinant E.Coli Acetate Kinase 5μg 20μg 1mg 112,200 220,800 3,600,400 ACO1 ENZ-056 Recombinant Human Aconitase-1 1μg 5μg 50μg 112,200 220,800 1,645,000 ACOT11 ENZ-756 Recombinant Human Acyl-CoA Thioesterase 11 5μg 20μg 1mg 112,200 220,800 3,600,400 ACOT11 ANT-424 Mouse Anti Human Acyl-Coenzyme A Thioesterase 11 5μg 20μg 100μg 112,200 220,800 664,800 ACOT13 ENZ-004 Recombinant Human Acyl-CoA Thioesterase 13 2μg 10μg 1mg 112,200 220,800 6,903,200 ACOT7 ENZ-214 Recombinant Human Acyl-CoA Thioesterase 7 5μg 20μg 1mg 112,200 220,800 3,600,400 ACOT7 ANT-462 Mouse Anti Human Acyl-Coenzyme A Thioesterase 7 5μg 20μg 100μg 112,200 220,800 664,800 ACOT8 ENZ-712 Recombinant Human Acyl-CoA Thioesterase 8 5μg 20μg 1mg 112,200 220,800 3,600,400 ACP1 ENZ-408 Recombinant Human Acid Phosphatase-1 5μg 20μg 1mg 112,200 220,800 4,879,000 ACP1 ANT-610 Mouse Anti Human Acid Phosphatase-1 5μg 20μg 100μg 112,200 220,800 664,800 ACP2 ENZ-849 Recombinant Human Acid Phosphatase-2 5μg 20μg 1mg 112,200 220,800 3,600,400 ACP5 ENZ-1025 Recombinant Human Acid Phosphatase-5 2μg 10μg 100μg 112,200 220,800 1,645,000 ACP5 His ENZ-913 Recombinant Human Acid Phosphatase-5 His Tag 2μg 10μg 1mg 112,200 220,800 6,903,200 ACP6 ENZ-865 Recombinant Human Acid Phosphatase-6 5μg 20μg 1mg 112,200 220,800 3,600,400 ACPP ENZ-847 Recombinant Human Acid Phosphatase Prostate 5μg 20μg 1mg 112,200 220,800 4,879,000 ACPP sf9 ENZ-968 Recombinant Human Acid Phosphatase Prostate, sf9 2μg 10μg 100μg 112,200 220,800 1,645,000 Acrp30 ANT-232 Mouse Anti Human Adiponectin 5μg 20μg 100μg 112,200 220,800 664,800 Acrp30 CYT-024 Human Adiponectin 2μg 10μg 0.1mg 90,500 199,000 1,388,000 � 쯚퐪욚훊5FM'BY 븲�ә�첾PSEFS!NFTEJBDPLS펦UFDI!NFTEJBDPLS List by Molecule Name .KUVD[/QNGEWNG0COG �칊�튾튪찋잖쐚찯짣흖흌쐚��XXXQSPTQFDCJPDPN흖튢�튾� ѣشۼࡒْɹ ࢒ɹٵܒ QNGEWNCT ࡅԘ/ ࢼૺ؞ୋ ࢼૺֵ 0COG #$% # $ % Acrp30 CYT-280 Recombinant Human Adiponectin 5μg 25μg 1mg 112,200 220,800 3,708,900 Acrp30 (108- CYT-073 Recombinant Human Adiponectin (108-244 a.a.) 5μg 25μg 1mg 112,200 220,800 3,708,900 244) Acrp30, HEK CYT-434 Recombinant Human Adiponectin glycosilated, HEK 2μg 10μg 1mg 90,500 199,000 7,174,300 Acrp30, His CYT-433 Recombinant Human Adiponectin, His tag 10μg 50μg 1mg 90,500 199,000 2,691,500 Acrp30, HMW CYT-764 Recombinant Human Adiponectin glycosilated, HMW Rich 2μg 10μg 1mg 90,500 199,000 7,174,300 Acrp30, Sf9 CYT-1002 Recombinant Human Adiponectin, Sf9 1μg 5μg 50μg 112,200 220,800 1,645,000 Acrp30, Tri CYT-233 Recombinant Human Adiponectin Trimeric Form 2μg 10μg 1mg 90,500 199,000 8,064,500 ACSF2 ENZ-919 Recombinant Human Acyl-CoA Synthetase Family Member 2 5μg 20μg 1mg 112,200 220,800 4,879,000 ACSF2 ANT-694 Mouse Anti Human Acyl-CoA Synthetase Family Member 2 5μg 20μg 100μg 112,200 220,800 664,800 ACTA1 ANT-749 Mouse Anti Human Actin 5μg 20μg 100μg 112,200 220,800 664,800 ACTA2 PRO-1220 Recombinant Human Actin, Alpha 2, Smooth Muscle, Aorta 2μg 10μg 1mg 112,200 220,800 6,903,200 ACTB ANT-687 Mouse Anti Human Actin Beta 5μg 20μg 100μg 112,200 220,800 664,800 ACTH HOR-279 Adrenocorticotropic Hormone 2mg 10mg 50mg 90,500 199,000 698,400 Actin PRO-517 Actin 10μg 50μg 1mg 90,500 199,000 2,425,700 Activin A CYT-569 Recombinant Human Activin-A 2μg 10μg 1mg 112,200 220,800 3,600,400 Activin A, CYT-145 Recombinant Human Activin-A, Active 2μg 10μg 1mg 90,500 199,000 5,547,800 Active Activin A, Plant CYT-052 Recombinant Human Activin-A, Plant 2μg 10μg 1mg 90,500 199,000 6,632,000 Activin A, CYT-414 Recombinant Human Activin-A Active 1μg 5μg 100μg 90,500 199,000 2,019,900 Plant-Active Activin B CYT-058 Recombinant Human Activin-B 2μg 10μg 1mg 90,500 199,000 6,632,000 Activin B, CYT-057 Recombinant Human Activin-B Active 2μg 10μg 1mg 90,500 199,000 7,355,000 Active Activin-A ANT-029 Polyclonal Rabbit Anti Human Activin-A 5μg 20μg 100μg 90,500 199,000 643,200 ACTN1 PRO-518 Actinin Alpha 1 10μg 50μg 1mg 90,500 199,000 3,210,400 ACTN1 PRO-2227 Recombinant Human Actinin Alpha 1 5μg 20μg 1mg 112,200 220,800 3,600,400 ACTN1 ANT-597 Mouse Anti Human Actinin Alpha 1 5μg 20μg 100μg 112,200 220,800 664,800 ACTR3 PRO-2096 Recombinant Human ARP3 Actin-Related Protein 3 5μg 20μg 1mg 112,200 220,800 3,600,400 ACVR1 CYT-1140 Recombinant Human Activin A Receptor Type 1 2μg 10μg 0.1mg 112,200 220,800 1,414,800 ACVR2A CYT-976 Recombinant Human Activin A Receptor Type 2A 2μg 10μg 1mg 112,200 220,800 6,903,200 ACVRL1 CYT-920 Recombinant Human Activin A Receptor Type II-Like 1 2μg 10μg 1mg 112,200 220,800 6,903,200 ACY1 ENZ-296 Recombinant Human AminoAcylase-1 2μg 10μg 1mg 112,200 220,800 6,397,200 ACY1 ANT-555 Mouse Anti Human AminoAcylase-1 5μg 20μg 100μg 112,200 220,800 664,800 ACY3 ENZ-153 Recombinant Human AminoAcylase-3 2μg 10μg 1mg 112,200 220,800 6,903,200 ACYP1 ENZ-078 Recombinant Human Acylphosphatase 1 5μg 20μg 1mg 112,200 220,800 3,600,400 ADA ENZ-147 Recombinant Human Adenosine Deaminase 2μg 10μg 1mg 112,200 220,800 6,903,200 ADAL ENZ-788 Recombinant Human Adenosine Deaminase-Like 5μg 20μg 1mg 112,200 220,800 3,600,400 ADAM10 PRO-476 Recombinant Human A Disintegrin and Metalloproteinase 2μg 10μg 1mg 112,200 220,800 6,397,200 Domain 10 ADAM10 Sf9 PRO-2359 Recombinant
Recommended publications
  • The 2021 List of Pharmacological Classes of Doping Agents and Doping Methods

    The 2021 List of Pharmacological Classes of Doping Agents and Doping Methods

    BGBl. III - Ausgegeben am 8. Jänner 2021 - Nr. 1 1 von 23 The 2021 list of pharmacological classes of doping agents and doping methods www.ris.bka.gv.at BGBl. III - Ausgegeben am 8. Jänner 2021 - Nr. 1 2 von 23 www.ris.bka.gv.at BGBl. III - Ausgegeben am 8. Jänner 2021 - Nr. 1 3 von 23 THE 2021 PROHIBITED LIST WORLD ANTI-DOPING CODE DATE OF ENTRY INTO FORCE 1 January 2021 Introduction The Prohibited List is a mandatory International Standard as part of the World Anti-Doping Program. The List is updated annually following an extensive consultation process facilitated by WADA. The effective date of the List is 1 January 2021. The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail. Below are some terms used in this List of Prohibited Substances and Prohibited Methods. Prohibited In-Competition Subject to a different period having been approved by WADA for a given sport, the In- Competition period shall in principle be the period commencing just before midnight (at 11:59 p.m.) on the day before a Competition in which the Athlete is scheduled to participate until the end of the Competition and the Sample collection process. Prohibited at all times This means that the substance or method is prohibited In- and Out-of-Competition as defined in the Code. Specified and non-Specified As per Article 4.2.2 of the World Anti-Doping Code, “for purposes of the application of Article 10, all Prohibited Substances shall be Specified Substances except as identified on the Prohibited List.
  • Biological, Physiological, Pathophysiological, and Pharmacological Aspects of Ghrelin

    Biological, Physiological, Pathophysiological, and Pharmacological Aspects of Ghrelin

    0163-769X/04/$20.00/0 Endocrine Reviews 25(3):426–457 Printed in U.S.A. Copyright © 2004 by The Endocrine Society doi: 10.1210/er.2002-0029 Biological, Physiological, Pathophysiological, and Pharmacological Aspects of Ghrelin AART J. VAN DER LELY, MATTHIAS TSCHO¨ P, MARK L. HEIMAN, AND EZIO GHIGO Division of Endocrinology and Metabolism (A.J.v.d.L.), Department of Internal Medicine, Erasmus Medical Center, 3015 GD Rotterdam, The Netherlands; Department of Psychiatry (M.T.), University of Cincinnati, Cincinnati, Ohio 45237; Endocrine Research Department (M.L.H.), Eli Lilly and Co., Indianapolis, Indiana 46285; and Division of Endocrinology (E.G.), Department of Internal Medicine, University of Turin, Turin, Italy 10095 Ghrelin is a peptide predominantly produced by the stomach. secretion, and influence on pancreatic exocrine and endo- Ghrelin displays strong GH-releasing activity. This activity is crine function as well as on glucose metabolism. Cardiovas- mediated by the activation of the so-called GH secretagogue cular actions and modulation of proliferation of neoplastic receptor type 1a. This receptor had been shown to be specific cells, as well as of the immune system, are other actions of for a family of synthetic, peptidyl and nonpeptidyl GH secre- ghrelin. Therefore, we consider ghrelin a gastrointestinal tagogues. Apart from a potent GH-releasing action, ghrelin peptide contributing to the regulation of diverse functions of has other activities including stimulation of lactotroph and the gut-brain axis. So, there is indeed a possibility that ghrelin corticotroph function, influence on the pituitary gonadal axis, analogs, acting as either agonists or antagonists, might have stimulation of appetite, control of energy balance, influence clinical impact.
  • Katalog 2015 Cover Paul Lin *Hinweis Förderung.Indd

    Katalog 2015 Cover Paul Lin *Hinweis Förderung.Indd

    Product List 2015 WE LIVE SERVICE Certificates quartett owns two productions sites that are certified according to EN ISO 9001:2008 Quality management systems - Requirements EN ISO 13485:2012 + AC:2012 Medical devices - Quality management systems - Requirements for regulatory purposes GMP Conformity Our quality management guarantees products of highest quality! 2 Foreword to the quartett product list 2015 quartett Immunodiagnostika, Biotechnologie + Kosmetik Vertriebs GmbH welcomes you as one of our new business partners as well as all of our previous loyal clients. You are now member of quartett´s worldwide customers. First of all we would like to introduce ourselves to you. Founded as a family-run company in 1986, quartett ensures for more than a quarter of a century consistent quality of products. Service and support of our valued customers are our daily businesses. And we will continue! In the end 80´s quartett offered radioimmunoassay and enzyme immunoassay kits from different manufacturers in the USA. In the beginning 90´s the company changed its strategy from offering products for routine diagnostic to the increasing field of research and development. Setting up a production plant in 1997 and a second one in 2011 supported this decision. The company specialized its product profile in the field of manufacturing synthetic peptides for antibody production, peptides such as protease inhibitors, biochemical reagents and products for histology, cytology and immunohistology. All products are exclusively manufactured in Germany without outsourcing any production step. Nowadays, we expand into all other diagnostic and research fields and supply our customers in universities, government institutes, pharmaceutical and biotechnological companies, hospitals, and private doctor offices.
  • Drug Testing Program

    Drug Testing Program

    DRUG TESTING PROGRAM Copyright © 2021 CrossFit, LLC. All Rights Reserved. CrossFit is a registered trademark ® of CrossFit, LLC. 2021 DRUG TESTING PROGRAM 2021 DRUG TESTING CONTENTS 1. DRUG-FREE COMPETITION 2. ATHLETE CONSENT 3. DRUG TESTING 4. IN-COMPETITION/OUT-OF-COMPETITION DRUG TESTING 5. REGISTERED ATHLETE TESTING POOL (OUT-OF-COMPETITION DRUG TESTING) 6. REMOVAL FROM TESTING POOL/RETIREMENT 6A. REMOVAL FROM TESTING POOL/WATCH LIST 7. TESTING POOL REQUIREMENTS FOLLOWING A SANCTION 8. DRUG TEST NOTIFICATION AND ADMINISTRATION 9. SPECIMEN ANALYSIS 10. REPORTING RESULTS 11. DRUG TESTING POLICY VIOLATIONS 12. ENFORCEMENT/SANCTIONS 13. APPEALS PROCESS 14. LEADERBOARD DISPLAY 15. EDUCATION 16. DIETARY SUPPLEMENTS 17. TRANSGENDER POLICY 18. THERAPEUTIC USE EXEMPTION APPENDIX A: 2020-2021 CROSSFIT BANNED SUBSTANCE CLASSES APPENDIX B: CROSSFIT URINE TESTING PROCEDURES - (IN-COMPETITION) APPENDIX C: TUE APPLICATION REQUIREMENTS Drug Testing Policy V4 Copyright © 2021 CrossFit, LLC. All Rights Reserved. CrossFit is a registered trademark ® of CrossFit, LLC. [ 2 ] 2021 DRUG TESTING PROGRAM 2021 DRUG TESTING 1. DRUG-FREE COMPETITION As the world’s definitive test of fitness, CrossFit Games competitions stand not only as testaments to the athletes who compete but to the training methodologies they use. In this arena, a true and honest comparison of training practices and athletic capacity is impossible without a level playing field. Therefore, the use of banned performance-enhancing substances is prohibited. Even the legal use of banned substances, such as physician-prescribed hormone replacement therapy or some over-the-counter performance-enhancing supplements, has the potential to compromise the integrity of the competition and must be disallowed. With the health, safety, and welfare of the athletes, and the integrity of our sport as top priorities, CrossFit, LLC has adopted the following Drug Testing Policy to ensure the validity of the results achieved in competition.
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus

    A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus

    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
  • Generated by SRI International Pathway Tools Version 25.0, Authors S

    Generated by SRI International Pathway Tools Version 25.0, Authors S

    An online version of this diagram is available at BioCyc.org. Biosynthetic pathways are positioned in the left of the cytoplasm, degradative pathways on the right, and reactions not assigned to any pathway are in the far right of the cytoplasm. Transporters and membrane proteins are shown on the membrane. Periplasmic (where appropriate) and extracellular reactions and proteins may also be shown. Pathways are colored according to their cellular function. Gcf_000238675-HmpCyc: Bacillus smithii 7_3_47FAA Cellular Overview Connections between pathways are omitted for legibility.
  • Glycerol Dehydrogenase from Gluconobacter Industrius

    Glycerol Dehydrogenase from Gluconobacter Industrius

    Agric. Biol Chem., 49 (4), 1001 -1010, 1985 1001 Solubilization, Purification and Properties of Membrane-bound Glycerol Dehydrogenase from Gluconobacter industrius Minoru Ameyama,Emiko Shinagawa, Kazunobu Matsushita and Osao Adachi Laboratory of Applied Microbiology, Department of Agricultural Chemistry, Faculty of Agriculture, Yamaguchi University, Yamaguchi 753, Japan Received July 30, 1984 Membrane-bound glycerol dehydrogenase was solubilized and purified about 100-fold from the membraneof Gluconobacter industrius IFO 3260 grown on a glycerol-glutamate medium. Solubilization of the enzyme was successfully achieved by use of 0.5% dimethyldodecylamineoxide in 0.05 m Tris-HCl, pH 8.0. Alcohol dehydrogenase and D-glucose dehydrogenase, which were abundantly formed in the same bacterial membrane, were eliminated on solubilization. Glycerol dehydrogenase was further purified through fractionation with polyethylene glycol 6000. The enzymeshowed a broad substrate specificity and various kinds of polyhydroxyl alcohols, in addition to glycerol, were rapidly oxidized in the presence of 2,6-dichlorophenolindophenoi and phenazine methosulfate as the electron acceptor but NADand NADPwere inert. The enzyme was proved to be a quinoprotein in which pyrroloquinoline quinone functioned as the prosthetic group. The first report on microbial oxidation of localization of the oxidase system in cells of G. glycerol to dihydroxyacetone was by Bertrand liquefaciens and found that the oxidation of with a strain capable of L-sorbose fermen- glycerol and raeso-erythritol
  • Recombinant Escheichia Coli-Catalyzed Production of Cytidine 5′-Triphosphate from Cytidine 5′-Monophosphate

    Recombinant Escheichia Coli-Catalyzed Production of Cytidine 5′-Triphosphate from Cytidine 5′-Monophosphate

    J. Ind. Eng. Chem., Vol. 12, No. 5, (2006) 757-761 Recombinant Escheichia coli-Catalyzed Production of Cytidine 5′-Triphosphate from Cytidine 5′-Monophosphate Sun-Gu Lee† and Byung-Gee Kim* Department of Chemical and Biochemical Engineering, Pusan National University, Busan 609-735, Korea *School of Chemical Engineering, and Institute of Molecular Biology and Genetics, Seoul National University, Seoul 151-742, Korea Received April 24, 2006; Accepted May 22, 2006 Abstract: A recombinant Escherichia coli overexpressing CMP-kinase was constructed and employed as a whole cell biocatalyst for the conversion of cytidine 5′-monophosphate to cytidine 5′-triphosphate. In the whole cell biocatalysis, recombinant CMP kinase catalyzed the conversion of CMP to CDP, and endogenous acetate kinase of the E. coli was utilized for the ATP regeneration as well as for the conversion of CDP to CTP. A conversion yield of ca. 88 % CTP was obtained when starting with 20 mM CMP, 1 mM ATP, and 80 mM acetyl phosphate based on the initial CMP concentration. Endogenous pyruvate kinase and poly- phosphate kinase were inefficient in the process. The CTP production system was applied to the production of CMP-NeuAc by additionally introducing the CMP-NeuAc synthetase gene into the recombinant E. coli. Keywords: CMP-kinase, whole cell biocatalysis, ATP regeneration, cytidine 5′-monophosphate Introduction employing enzymes [4]. They applied various enzymatic 1) methods and chemical methods and concluded that the As glycosyltransferase-catalyzed synthetic techniques enzymatic method based on adenylate kinase/pyruvate are becoming recognized as powerful methods for the kinase provided the most convenient route to CTP. In the preparation of biologically important oligosaccharides, process, CTP was generated efficiently from an inexpen- the development of cost-efficient production methods for sive substrate, CMP.
  • Découverte D'une Nouvelle Famille De Protéine Kinases Bactériennes

    Découverte D'une Nouvelle Famille De Protéine Kinases Bactériennes

    Découverte d’une nouvelle famille de protéine kinases bactériennes : mécanismes de fonctionnement et rôle cellulaire de YdiB, un archétype chez Baccillus subtilis Hien-Anh Nguyen To cite this version: Hien-Anh Nguyen. Découverte d’une nouvelle famille de protéine kinases bactériennes : mécanismes de fonctionnement et rôle cellulaire de YdiB, un archétype chez Baccillus subtilis. Sciences agricoles. Université de Grenoble, 2012. Français. NNT : 2012GRENV017. tel-00721757 HAL Id: tel-00721757 https://tel.archives-ouvertes.fr/tel-00721757 Submitted on 30 Jul 2012 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. THÈSE Pour obtenir le grade de DOCTEUR DE L’UNIVERSITÉ DE GRENOBLE Spécialité : Chimie-Biologie Arrêté ministériel : 7 août 2006 Présentée par Hien-Anh NGUYEN Thèse dirigée par le Dr. Jean-Michel JAULT préparée au sein de l’Institut de Biologie Structurale J.-P. Ebel, et du CEA de Grenoble dans l'École Doctorale Chimie et Sciences du Vivant Découverte d’une nouvelle famille de protéines kinases bactériennes : Mécanisme de fonctionnement et rôle cellulaire de YdiB, un représentant chez B. subtilis Thèse soutenue publiquement le 23 mai 2012 devant le jury composé de : Mme. Patricia DOUBLET Rapporteur Prof.
  • Cellular and Molecular Signatures in the Disease Tissue of Early

    Cellular and Molecular Signatures in the Disease Tissue of Early

    Cellular and Molecular Signatures in the Disease Tissue of Early Rheumatoid Arthritis Stratify Clinical Response to csDMARD-Therapy and Predict Radiographic Progression Frances Humby1,* Myles Lewis1,* Nandhini Ramamoorthi2, Jason Hackney3, Michael Barnes1, Michele Bombardieri1, Francesca Setiadi2, Stephen Kelly1, Fabiola Bene1, Maria di Cicco1, Sudeh Riahi1, Vidalba Rocher-Ros1, Nora Ng1, Ilias Lazorou1, Rebecca E. Hands1, Desiree van der Heijde4, Robert Landewé5, Annette van der Helm-van Mil4, Alberto Cauli6, Iain B. McInnes7, Christopher D. Buckley8, Ernest Choy9, Peter Taylor10, Michael J. Townsend2 & Costantino Pitzalis1 1Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK. Departments of 2Biomarker Discovery OMNI, 3Bioinformatics and Computational Biology, Genentech Research and Early Development, South San Francisco, California 94080 USA 4Department of Rheumatology, Leiden University Medical Center, The Netherlands 5Department of Clinical Immunology & Rheumatology, Amsterdam Rheumatology & Immunology Center, Amsterdam, The Netherlands 6Rheumatology Unit, Department of Medical Sciences, Policlinico of the University of Cagliari, Cagliari, Italy 7Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow G12 8TA, UK 8Rheumatology Research Group, Institute of Inflammation and Ageing (IIA), University of Birmingham, Birmingham B15 2WB, UK 9Institute of
  • Dissecting the Transcriptional Phenotype of Ribosomal Protein Deficiency: Implications for Diamond-Blackfan Anemia

    Dissecting the Transcriptional Phenotype of Ribosomal Protein Deficiency: Implications for Diamond-Blackfan Anemia

    Gene 545 (2014) 282–289 Contents lists available at ScienceDirect Gene journal homepage: www.elsevier.com/locate/gene Short Communication Dissecting the transcriptional phenotype of ribosomal protein deficiency: implications for Diamond-Blackfan Anemia Anna Aspesi a, Elisa Pavesi a, Elisa Robotti b, Rossella Crescitelli a,IleniaBoriac, Federica Avondo a, Hélène Moniz d, Lydie Da Costa d, Narla Mohandas e,PaolaRoncagliaf, Ugo Ramenghi g, Antonella Ronchi h, Stefano Gustincich f,SimoneMerlina,EmilioMarengob, Steven R. Ellis i, Antonia Follenzi a, Claudio Santoro a, Irma Dianzani a,⁎ a Department of Health Sciences, University of Eastern Piedmont, Novara, Italy b Department of Sciences and Technological Innovation, University of Eastern Piedmont, Alessandria, Italy c Department of Chemistry, University of Milan, Italy d U1009, AP-HP, Service d'Hématologie Biologique, Hôpital Robert Debré, Université Paris VII-Denis Diderot, Sorbonne Paris Cité, F-75475 Paris, France e New York Blood Center, NY, USA f International School for Advanced Studies (SISSA/ISAS), Trieste, Italy g Department of Pediatric Sciences, University of Torino, Torino, Italy h Department of Biotechnologies and Biosciences, Milano-Bicocca University, Italy i University of Louisville, KY, USA article info abstract Article history: Defects in genes encoding ribosomal proteins cause Diamond Blackfan Anemia (DBA), a red cell aplasia often as- Received 3 December 2013 sociated with physical abnormalities. Other bone marrow failure syndromes have been attributed to defects in Received in revised form 4 April 2014 ribosomal components but the link between erythropoiesis and the ribosome remains to be fully defined. Several Accepted 29 April 2014 lines of evidence suggest that defects in ribosome synthesis lead to “ribosomal stress” with p53 activation and Available online 15 May 2014 either cell cycle arrest or induction of apoptosis.
  • Lapatinib Activates the Kelch-Like ECH- Associated Protein 1-Nuclear Factor Erythroid 2-Related Factor 2 Pathway in Hepg2 Cells

    Lapatinib Activates the Kelch-Like ECH- Associated Protein 1-Nuclear Factor Erythroid 2-Related Factor 2 Pathway in Hepg2 Cells

    Updates in Pharmacology Book Chapter Lapatinib Activates the Kelch-Like ECH- Associated Protein 1-Nuclear Factor Erythroid 2-Related Factor 2 Pathway in HepG2 Cells Noëmi Johanna Roos1,2,3, Diell Aliu1,2, Jamal Bouitbir1,2,3 and Stephan Krähenbühl1,2,3* 1Division of Clinical Pharmacology & Toxicology, University Hospital, Switzerland 2Department of Biomedicine, University of Basel, Switzerland 3Swiss Centre for Applied Human Toxicology (SCAHT), Switzerland *Corresponding Author: Stephan Krähenbühl, Division of Clinical Pharmacology & Toxicology, University Hospital, Basel, Switzerland Published October 26, 2020 This Book Chapter is a republication of an article published by Stephan Krähenbühl, et al. at Frontiers in Pharmacology in June 2020. (Roos NJ, Aliu D, Bouitbir J and Krähenbühl S (2020) Lapatinib Activates the Kelch-Like ECH-Associated Protein 1- Nuclear Factor Erythroid 2-Related Factor 2 Pathway in HepG2 Cells. Front. Pharmacol. 11:944. doi: 10.3389/fphar.2020.00944) How to cite this book chapter: Noëmi Johanna Roos, Diell Aliu, Jamal Bouitbir, Stephan Krähenbühl. Lapatinib Activates the Kelch-Like ECH-Associated Protein 1-Nuclear Factor Erythroid 2-Related Factor 2 Pathway in HepG2 Cells. In: Nosheen Akhtar, editor. Updates in Pharmacology. Hyderabad, India: Vide Leaf. 2020. © The Author(s) 2020. This article is distributed under the terms of the Creative Commons Attribution 4.0 International 1 www.videleaf.com Updates in Pharmacology License(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Data Availability Statement: All datasets for this study are included in the figshare repository: https://doi.org/10.6084/m9.figshare.12034608.v1.